Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
109.5 USD | -0.25% | -3.23% | -11.00% |
05-13 | US reclassification could drive fresh research funding into pot sector | RE |
05-07 | Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.00% | 6.92B | |
+33.17% | 709B | |
+30.77% | 595B | |
-1.73% | 367B | |
+20.23% | 334B | |
+5.55% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.15% | 171B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- RBC Capital Adjusts Jazz Pharmaceuticals Price Target to $207 From $203, Maintains Outperform Rating